Skip to main content

Table 1 Patient information. The reported administered activities correspond to the dose-calibrator readings corrected for Lipiodol attenuation. The liver volumes were derived from pre-treatment contrast-enhanced CT images except for patients 3 and 8, which were derived from post-treatment SPECT/CT images

From: Biodistribution, pharmacokinetics, and organ-level dosimetry for 188Re-AHDD-Lipiodol radioembolization based on quantitative post-treatment SPECT/CT scans

Patient no.

Age [year]

Sex

Injected Act. [MBq]

Imaging time post-injection [h]

Tumor volume [cc]

Liver volume [cc]

t 1

t 2

t 3

1*

64

M

3405

2.7

26.3

50.3

13

1012

2*

69

M

6013

3.6

27.8

N/A

240

1200

3*

33

M

7162

5.2

27.5

52.6

1000

4030

4

59

M

1296

1.3

27.7

N/A

22

1194

5

71

M

1527

4.6

27.3

N/A

10

975

6

46

F

1750

3.1

24.7

49.2

400

1300

7a

20

F

5239

4.2

29.1

N/A

600

1400

7b

20

F

5559

3.6

28.2

51.3

150

1400

8*

51

M

2479

3.0

26.6

42.8

11

1260

9

53

M

2444

1.6

25.4

47.0

65

1300

10

72

M

2284

5.5

26.5

56.1

10

1300

11

68

M

1722

2.6

27.0

51.4

90

1152

12

62

M

2602

3.8

27.4

49.8

340

1200

13

71

M

1637

3.8

24.9

44.7

2.3

800

  1. *Tomographic data in these patients were acquired without scatter windows. In these cases, the scatter was compensated using the attenuation map with broad-beam attenuation coefficients